Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase 3
- Conditions
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 950
- Registration Number
- NCT00435851
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Image Guided Radiation Therapy For Prostate Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 470
- Registration Number
- NCT00433706
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 48
- Registration Number
- NCT00418327
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Registration Number
- NCT00412503
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, Ille de France, France
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 500
- Registration Number
- NCT00410683
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, Val De Marne, France
Clinical Studies of Gemcitabine-Oxaliplatin
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 156
- Registration Number
- NCT00407433
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1993
- Registration Number
- NCT00359645
- Locations
- 🇫🇷
CHIAB Annemasse Bonneville, Annemasse, France
🇫🇷Centre Hospitalier MONTPERRIN, Aix en Provence, France
🇫🇷CHU Hôpital Gabriel Montpied, Clermont-ferrand, France
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
Phase 2
- Conditions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2006-10-06
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 67
- Registration Number
- NCT00349505
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 46
- Registration Number
- NCT00346645
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
Not Applicable
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 310
- Registration Number
- NCT00232960
- Locations
- 🇫🇷
Hôpital de la Croix Rousse, Lyon, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Alexis Vautrin, Vandoeuvre les Nancy, France
© Copyright 2024. All Rights Reserved by MedPath